ADCC-enhanced CTLA-4 Antibody of ImmuneOnco Received Approval of NMPA for Clinical Trial
Date：2021-11-05 Views：1016
On November 4, 2021, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that IMM27M, the newly developed ADCC-enhanced CTLA-4 antibody was approved by NMPA for clinical trial research. This is another major milestone for ImmueOnco.
CTLA-4 is the first clinically proven check point for immunotherapy, as the first antibody approved in 2011, Ipilimumab is still the only approved drug in the global market. Three weeks ago, the first prescription came out priced at￥28,000 per dose in China.
The IMM27M is an IgG1 antibody targeting CTLA-4. It has been genetically modified to enhance ADCC activity. In the preclinical research, IMM27M appeared to be more efficacious than that of Ipilimumab since it completely removes tumors at a lower dose (0.3 mg/kg) in animal models.
Dr. Tian, Wenzhi, the founder and chairman of ImmueOnco said,
"We are pleased that our next-generation CTLA-4 antibody program has been approved by NMPA for clinical trial research. Repeatable in vivo studies have demonstrated that IMM27M has robust anti-tumor activity and also, can be used in combination with a variety of drugs in the company's pipeline for clinical research. We believe that the IMM27M has great value for clinical development. ”
"We will make our best to develop IMM27M to benefit more patients."
About IMM27M
IMM27M is a new generation of CTLA-4 antibody developed by ImmueOnco. By genetic engineering modification, the ADCC activity has been greatly enhanced so as to eliminate Treg cells completely from tumor microenvironment. IMM27M is, not only efficacious in mono drug therapy, but also could be administrated in combination with a variety of drug candidates in the product pipeline such as IMM01 (CD47), IMM2510 (VEGF/PD-L1), IMM2902 (CD47/Her2), IMM2520 (CD47/PD-L1).
About ImmuneOnco
Founded in June 2015 in the Zhangjiang Hi-Tech Park of the China (Shanghai) Pilot Free Trade Zone, ImmuneOnco focuses on the development and research of anti-tumor immunotherapy products, including bi-specific antibodies, novel recombinant proteins, and TankTM cellular therapy. The common feature of these products is to activate the patient's own immune system to exert the anti-tumor effects, and ultimately inhibit the endless growth of tumor cells and reverse the malignant symptoms, so that the patients gradually return to healthy. So far, several new anti-tumor drugs are in clinical research stage.
ImmuneOnco is recognized by authorities as one of the ‘Top 50 Start-up Enterprises with the Most Investment Potential in Shanghai’ in 2016, the "Excellent Enterprise" in the 2017 China Innovation and Entrepreneurship Competition, and the "Enterprise Excellence Award" of Shanghai Science and Technology Entrepreneurship in 2017.